Prevention of Typhoid Fever by Existing Improvements in Household Water, Sanitation, and Hygiene, and the Use of the Vi Polysaccharide Typhoid Vaccine in Poor Urban Slums: Results from a Cluster-Randomized Trial

Modest improvements in household water, sanitation, and hygiene (WASH) and typhoid vaccination can reduce typhoid risk in endemic settings. However, empiric evaluation of their combined impact is lacking. A total of 62,756 persons residing in 80 clusters in a Kolkata slum were allocated randomly 1:1...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of tropical medicine and hygiene Vol. 106; no. 4; pp. 1149 - 1155
Main Authors Im, Justin, Khanam, Farhana, Ahmmed, Faisal, Kim, Deok Ryun, Kang, Sophie, Tadesse, Birkneh Tilahun, Chowdhury, Fahima, Ahmed, Tasnuva, Aziz, Asma Binte, Hoque, Masuma, Islam, Md Taufiqul, Park, Juyeon, Liu, Xinxue, Sur, Dipika, Pak, Gideok, Jeon, Hyon Jin, Zaman, Khalequ, Khan, Ashraful Islam, Qadri, Firdausi, Marks, Florian, Kim, Jerome H, Clemens, John D
Format Journal Article
LanguageEnglish
Published United States Institute of Tropical Medicine 01.04.2022
The American Society of Tropical Medicine and Hygiene
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Modest improvements in household water, sanitation, and hygiene (WASH) and typhoid vaccination can reduce typhoid risk in endemic settings. However, empiric evaluation of their combined impact is lacking. A total of 62,756 persons residing in 80 clusters in a Kolkata slum were allocated randomly 1:1 to either the typhoid Vi polysaccharide (ViPS) vaccine or hepatitis A (Hep A) vaccine. Surveillance was conducted for 2 years before and 2 years after vaccination. We classified households as having "better" or "not better" WASH, and calculated the prevalence of better WASH households in clusters using previously validated criteria. We evaluated the protection by better household WASH, better household WASH prevalence, and ViPS vaccination against typhoid in all cluster members present at baseline using Cox proportional hazard models. Overall, ViPS vaccination was associated with a 55% (P < 0.001; 95% CI, 35-69) reduction of typhoid risk and was similar regardless of better WASH in the residence. Living in a better WASH household was associated with a typhoid risk reduction of 31% (P = 0.16; 95% CI, -16 to 59) overall. The reduction was 48% (P = 0.05; 95% CI, -1 to 73) in Hep A clusters, 6% (P = 0.85; 95% CI, -82 to 51) in ViPS clusters, and 57% (P < 0.05; 95% CI, 15-78) in the population during the 2 years preceding the trial. These findings demonstrate a preventive association of better household WASH in the non-ViPS population, but, unexpectedly, an absence of additional protection from ViPS by better WASH in the ViPS population. This analysis highlights the importance of assessing the combination of WASH in conjunction with typhoid vaccines, and has implications for the evaluation of new-generation typhoid conjugate vaccines.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Financial support: This publication was made possible through a grant from the Bill & Melinda Gates Foundation (INV-025386).
These authors contributed equally to this work.
Authors’ addresses: Justin Im, Deok Ryun Kim, Sophie Kang, Birkneh Tilahun Tadesse, Asma Binte Aziz, Gideok Pak, Jerome H. Kim, International Vaccine Institute, Seoul, Republic of Korea, E-mails: justin.im@ivi.int, drkim@ivi.int, sophie.kang@ivi.int, birkneh.tadesse@ivi.int, asma.aziz@ivi.int, gdpak@ivi.int, and jerome.kim@ivi.int. Farhana Khanam, Faisal Ahmmed, Fahima Chowdhury, Tasnuva Ahmed, Masuma Hoque, Md. Taufiqul Islam, Khalequ Zaman, Ashraful Islam Khan, and Firdausi Qadri, International Centre for Diarrheal Disease Research, Bangladesh, Dhaka, Bangladesh, E-mails: farhanak@icddrb.org, faisal.ahmmed@icddrb.org, fchowdhury@icddrb.org, tasnuva.ahmed@icddrb.org, masuma.hoque@icddrb.org, taufiqulislam@icddrb.org, kzaman@icddrb.org, ashrafk@icddrb.org, and fqadri@icddrb.org. Juyeon Park and Hyon Jin Jeon, International Vaccine Institute, Seoul, Republic of Korea, and Department of Medicine, University of Cambridge, Cambridge, UK, E-mails: juyeon.park@ivi.int and hyonjin.jeon@ivi.int. Xinxue Liu, Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK, E-mail: xinxue.liu@paediatrics.ox.ac.uk. Dipika Sur, National Institute of Cholera and Enteric Diseases, Kolkata, West Bengal, India, E-mail: dipikasur@hotmail.com. Florian Marks, International Vaccine Institute, Seoul, Republic of Korea, Department of Medicine, University of Cambridge, Cambridge, UK, and University of Antananarivo, Antananarivo, Madagascar, E-mail: fmarks@ivi.int. John D. Clemens, International Vaccine Institute, Seoul, Republic of Korea, International Centre for Diarrheal Disease Research, Bangladesh, Dhaka, Bangladesh, and University of California Los Angeles Fielding School of Public Health, Los Angeles, CA, E-mail: john.clemens@ivi.int.
ISSN:0002-9637
1476-1645
1476-1645
DOI:10.4269/ajtmh.21-1034